BidaskClub upgraded shares of NeuroDerm Ltd. (NASDAQ:NDRM) from a sell rating to a hold rating in a report issued on Tuesday.

Other equities research analysts have also issued reports about the stock. Deutsche Bank AG initiated coverage on shares of NeuroDerm in a research note on Friday, July 21st. They set a buy rating and a $47.00 target price for the company. Roth Capital set a $33.00 target price on shares of NeuroDerm and gave the company a buy rating in a research note on Wednesday, June 14th. Jefferies Group LLC reiterated a buy rating and set a $42.00 target price on shares of NeuroDerm in a research note on Monday, April 24th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of NeuroDerm in a research note on Sunday, May 14th. Finally, Zacks Investment Research lowered shares of NeuroDerm from a buy rating to a hold rating in a research note on Wednesday, April 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $43.38.

Shares of NeuroDerm (NDRM) remained flat at $38.85 during mid-day trading on Tuesday. 331,687 shares of the company traded hands. The company has a 50 day moving average price of $30.47 and a 200-day moving average price of $26.39. NeuroDerm has a 12-month low of $15.20 and a 12-month high of $38.85. The firm’s market cap is $1.02 billion.

NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.13. Equities analysts predict that NeuroDerm will post ($2.00) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/neuroderm-ltd-nasdaqndrm-upgraded-to-hold-by-bidaskclub/1461825.html.

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in NeuroDerm during the fourth quarter valued at approximately $1,797,000. Bank of Montreal Can bought a new position in NeuroDerm during the first quarter valued at approximately $266,000. Nationwide Fund Advisors bought a new position in NeuroDerm during the first quarter valued at approximately $226,000. NJ State Employees Deferred Compensation Plan bought a new position in NeuroDerm during the first quarter valued at approximately $266,000. Finally, Menora Mivtachim Holdings LTD. increased its position in NeuroDerm by 17.9% in the first quarter. Menora Mivtachim Holdings LTD. now owns 681,556 shares of the biotechnology company’s stock valued at $18,095,000 after buying an additional 103,582 shares during the period. Institutional investors and hedge funds own 52.32% of the company’s stock.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Analyst Recommendations for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.